Would you consider a trial of anti-PD-1 therapy following disease progression through anti-PD-L1 therapy for advanced urothelial carcinoma?

This is a great question and should be answered in a clinical trial setting. We need trials in patients with progression on anti-PDL1 or anti-PD1 agent; currently we don't have data to answer this question of cross-resistance